DOCSLIB.ORG

Supplementary Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Data Supplemental Data Microarray data analysis. In order to identify differentially expressed genes, we compared the melanoma samples to the benign nevi and the normal skin samples separately. The first analysis consisted of the 45 melanoma and 7 normal skin samples; the second analysis consisted of 45 melanoma and 18 nevi samples (Fig. S1). Significance analysis of microarray (SAM) was performed (17). Parameters for SAM were set as ∆=2.5 and fold change = 2.0 with 1,000 permutations. FDR was 1%. There was no missing data and the default random number was used. Next, percentile analysis was conducted. For up-regulated genes, the 30%ile in melanoma samples was compared to the maximum of the normal samples, or that of nevi samples. Student T-test with Bonferroni correction was also performed with cut-off p<0.05 in order to ensure that the selected genes had significant differential expression between the two groups of the samples. As a final step, we identified common genes between the melanoma/benign and melanoma /normal gene lists and reported a single list of genes up-regulated in melanoma (Table S1). 1 Fig. S1. 22,283 genes on Affymetrix U33a chip 15,795 genes with 2 or more “Present” calls Melanoma vs. Skin Melanoma vs. Benign nevi SAM FDR < 1%, fold-change > 2 2,326 up-regulated genes in cancer 828 up-regulated genes in cancer Percentile analysis Up-regulated in > 30% of melanoma 1,941 genes 527 genes T test with Bonferroni correction P < 0.05 592 genes (439 common genes) 492 genes 2 Table S1. Up-regulated genes in melanoma Median Expression Fold Change Fold Change PSID in Melanoma (Can vs Benign) (Can vs skin) 215025_at 2365 149 93 Consensus includes gb:S76476.1 /DEF=trkC {alternatively spliced} human, brain, mRNA, 2225 nt. /FEA=mRNA /GEN= 215311_at 10093 86 30 Consensus includes gb:AL109696.1 /DEF=Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 21920. /F 213960_at 11768 80 29 Consensus includes gb:T87225 /FEA=EST /DB_XREF=gi:715577 /DB_XREF=est:yc81f06.s1 /CLONE=IMAGE:22392 219478_at 5485 80 18 gb:NM_021197.1 /DEF=Homo sapiens WAP four-disulfide core domain 1 (WFDC1), mRNA. /FEA=mRNA /GEN=WFD 206462_s_at 9953 53 24 gb:NM_002530.1 /DEF=Homo sapiens neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), mRNA. /FEA=mRNA / 218839_at 1996 38 7 gb:NM_012258.1 /DEF=Homo sapiens hairyenhancer-of-split related with YRPW motif 1 (HEY1), mRNA. /FEA=mRN 215115_x_at 12421 34 15 Consensus includes gb:AI613045 /FEA=EST /DB_XREF=gi:4622212 /DB_XREF=est:ty68g03.x1 /CLONE=IMAGE:22 221577_x_at 4897 28 38 gb:AF003934.1 /DEF=Homo sapiens prostate differentiation factor mRNA, complete cds. /FEA=mRNA /PROD=prostate 217377_x_at 12402 27 18 Consensus includes gb:AF041811.2 /DEF=Homo sapiens ETS related protein-growth factor receptor tyrosine kinase fusi 213638_at 1827 26 102 Consensus includes gb:AW054711 /FEA=EST /DB_XREF=gi:5920414 /DB_XREF=est:wz96g08.x1 /CLONE=IMAGE 204709_s_at 312 24 16 gb:NM_004856.3 /DEF=Homo sapiens kinesin-like 5 (mitotic kinesin-like protein 1) (KNSL5), mRNA. /FEA=mRNA /G 221909_at 243 22 17 Consensus includes gb:AW299700 /FEA=EST /DB_XREF=gi:6709377 /DB_XREF=est:xs42g04.x1 /CLONE=IMAGE:2 204584_at 9677 21 15 Consensus includes gb:AI653981 /FEA=EST /DB_XREF=gi:4737960 /DB_XREF=est:ty04c03.x1 /CLONE=IMAGE:22 217033_x_at 10961 21 19 Consensus includes gb:S76475.1 /DEF=trkC human, brain, mRNA, 2715 nt. /FEA=mRNA /GEN=trkC /DB_XREF=gi:9 209875_s_at 3038 21 12 gb:M83248.1 /DEF=Human nephropontin mRNA, complete cds. /FEA=mRNA /GEN=nephropontin /PROD=nephropont 217624_at 349 21 20 Consensus includes gb:AA464753 /FEA=EST /DB_XREF=gi:2189637 /DB_XREF=est:zx86c10.s1 /CLONE=IMAGE:8 203071_at 958 19 3 gb:NM_004636.1 /DEF=Homo sapiens sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semap 213587_s_at 10416 18 9 Consensus includes gb:AI884867 /FEA=EST /DB_XREF=gi:5590031 /DB_XREF=est:wl85g03.x1 /CLONE=IMAGE:24 221815_at 3293 17 144 Consensus includes gb:BE671816 /FEA=EST /DB_XREF=gi:10032446 /DB_XREF=est:7a47d01.x1 /CLONE=IMAGE: 219578_s_at 1419 17 26 gb:NM_030594.1 /DEF=Homo sapiens hypothetical protein FLJ13203 similar to cytoplasmic polyadenylation element bi 207144_s_at 593 17 24 gb:NM_004143.1 /DEF=Homo sapiens Cbpp300-interacting transactivator, with GluAsp-rich carboxy-terminal domain, 203069_at 560 15 13 gb:NM_014849.1 /DEF=Homo sapiens KIAA0736 gene product (KIAA0736), mRNA. /FEA=mRNA /GEN=KIAA0736 63825_at 10096 14 74 Cluster Incl. AI557319:PT2.1_16_F08.r Homo sapiens cDNA, 3 end /clone_end=3 /gb=AI557319 /gi=4489682 /ug=Hs 44783_s_at 8503 14 6 Cluster Incl. R61374:yh15e02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-37665 /clone_end=3 /gb=R61374 /gi=832 218678_at 11356 14 20 gb:NM_024609.1 /DEF=Homo sapiens hypothetical protein FLJ21841 (FLJ21841), mRNA. /FEA=mRNA /GEN=FLJ21 219152_at 365 13 10 gb:NM_015720.1 /DEF=Homo sapiens endoglycan (PODLX2), mRNA. /FEA=mRNA /GEN=PODLX2 /PROD=endogly 205447_s_at 567 13 5 Consensus includes gb:BE222201 /FEA=EST /DB_XREF=gi:8909519 /DB_XREF=est:hu09a10.x1 /CLONE=IMAGE:3 204585_s_at 805 13 17 gb:NM_000425.2 /DEF=Homo sapiens L1 cell adhesion molecule (hydrocephalus, stenosis of aqueduct of Sylvius 1, MA 213274_s_at 18263 12 26 Consensus includes gb:AA020826 /FEA=EST /DB_XREF=gi:1484570 /DB_XREF=est:ze64b04.s1 /CLONE=IMAGE:3 219555_s_at 402 12 21 gb:NM_018455.1 /DEF=Homo sapiens uncharacterized bone marrow protein BM039 (BM039), mRNA. /FEA=mRNA / 203827_at 3380 11 8 gb:NM_017983.1 /DEF=Homo sapiens hypothetical protein FLJ10055 (FLJ10055), mRNA. /FEA=mRNA /GEN=FLJ10 3 205813_s_at 430 11 9 gb:NM_000429.1 /DEF=Homo sapiens methionine adenosyltransferase I, alpha (MAT1A), mRNA. /FEA=mRNA /GEN= 201850_at 11103 10 20 gb:NM_001747.1 DEF=Homo sapiens capping protein (actin filament), gelsolin-like (CAPG), mRNA. FEA=mRNA G 205373_at 579 10 8 gb:NM_004389.1 /DEF=Homo sapiens catenin (cadherin-associated protein), alpha 2 (CTNNA2), mRNA. /FEA=mRNA 214614_at 542 10 9 Consensus includes gb:AI738662 /FEA=EST /DB_XREF=gi:5100643 /DB_XREF=est:wi11f11.x1 /CLONE=IMAGE:23 213217_at 5848 10 6 Consensus includes gb:AU149572 /FEA=EST /DB_XREF=gi:11011093 /DB_XREF=est:AU149572 /CLONE=NT2RM4 204014_at 7184 10 46 gb:NM_001394.2 /DEF=Homo sapiens dual specificity phosphatase 4 (DUSP4), mRNA. /FEA=mRNA /GEN=DUSP4 /P 214893_x_at 214 10 9 Consensus includes gb:AI421964 /FEA=EST /DB_XREF=gi:4267895 /DB_XREF=est:tf40a10.x1 /CLONE=IMAGE:20 220178_at 5915 9 15 gb:NM_021731.1 /DEF=Homo sapiens hypothetical protein PP3501 (PP3501), mRNA. /FEA=mRNA /GEN=PP3501 /PR 202779_s_at 3400 9 55 gb:NM_014501.1 /DEF=Homo sapiens ubiquitin carrier protein (E2-EPF), mRNA. /FEA=mRNA /GEN=E2-EPF /PROD 207038_at 1986 9 47 gb:NM_004694.1 /DEF=Homo sapiens solute carrier family 16 (monocarboxylic acid transporters), member 6 (SLC16A6 219143_s_at 3618 9 13 gb:NM_017793.1 /DEF=Homo sapiens hypothetical protein FLJ20374 (FLJ20374), mRNA. /FEA=mRNA /GEN=FLJ20 214068_at 2148 9 10 Consensus includes gb:AF070610.1 /DEF=Homo sapiens clone 24505 mRNA sequence. /FEA=mRNA /DB_XREF=gi:3 201954_at 25901 9 15 gb:NM_005720.1 /DEF=Homo sapiens actin related protein 23 complex, subunit 1A (41 kD) (ARPC1B), mRNA. /FEA= 214841_at 913 9 11 Consensus includes gb:AF070524.1 /DEF=Homo sapiens clone 24453 mRNA sequence. /FEA=mRNA /DB_XREF=gi:3 206307_s_at 534 8 4 gb:NM_004472.1 /DEF=Homo sapiens forkhead box D1 (FOXD1), mRNA. /FEA=mRNA /GEN=FOXD1 /PROD=forkh 205681_at 1316 8 12 gb:NM_004049.1 /DEF=Homo sapiens BCL2-related protein A1 (BCL2A1), mRNA. /FEA=mRNA /GEN=BCL2A1 /PR 206503_x_at 419 8 9 gb:NM_002675.1 /DEF=Homo sapiens promyelocytic leukemia (PML), mRNA. /FEA=mRNA /GEN=PML /PROD=pro 205690_s_at 9179 8 9 gb:NM_003910.1 /DEF=Homo sapiens maternal G10 transcript (G10), mRNA. /FEA=mRNA /GEN=G10 /PROD=mater 203878_s_at 2036 8 5 gb:NM_005940.2 /DEF=Homo sapiens matrix metalloproteinase 11 (stromelysin 3) (MMP11), mRNA. /FEA=mRNA /G 211013_x_at 498 8 13 gb:AF230411.1 /DEF=Homo sapiens tripartite motif protein TRIM19 lambda mRNA, complete cds. /FEA=mRNA /PRO 209256_s_at 4949 8 6 gb:AF277177.1 /DEF=Homo sapiens PNAS-119 mRNA, complete cds. /FEA=mRNA /PROD=PNAS-119 /DB_XREF=g 215126_at 4940 8 19 Consensus includes gb:AL109716.2 /DEF=Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 208948. / 214896_at 3071 8 11 Consensus includes gb:AL109671.1 /DEF=Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 29222. /F 200838_at 19225 8 17 gb:NM_001908.1 /DEF=Homo sapiens cathepsin B (CTSB), mRNA. /FEA=mRNA /GEN=CTSB /PROD=cathepsin B /D 213836_s_at 2605 8 5 Consensus includes gb:AW052084 /FEA=EST /DB_XREF=gi:5914443 /DB_XREF=est:wy86f07.x1 /CLONE=IMAGE: 209053_s_at 269 7 10 Consensus includes gb:BE793789 /FEA=EST /DB_XREF=gi:10214987 /DB_XREF=est:601589946F1 /CLONE=IMAG 209827_s_at 4884 7 7 Consensus includes gb:NM_004513.1 /DEF=Homo sapiens interleukin 16 (lymphocyte chemoattractant factor) (IL16), m 214023_x_at 1602 7 9 Consensus includes gb:AL533838 /FEA=EST /DB_XREF=gi:12797331 /DB_XREF=est:AL533838 /CLONE=CS0DF00 209848_s_at 32959 7 74 gb:U01874.1 /DEF=Human me20m mRNA, complete cds. /FEA=mRNA /PROD=me20m /DB_XREF=gi:494939 /UG=H 206696_at 6446 7 191 gb:NM_000273.1 /DEF=Homo sapiens ocular albinism 1 (Nettleship-Falls) (OA1), mRNA. /FEA=mRNA /GEN=OA1 /P 218330_s_at 3853 7 4 gb:NM_018162.1 /DEF=Homo sapiens hypothetical protein FLJ10633 (FLJ10633), mRNA. /FEA=mRNA /GEN=FLJ10 213275_x_at 17604 7 3 Consensus includes gb:W47179 /FEA=EST /DB_XREF=gi:1332046 /DB_XREF=est:zc34d07.s1 /CLONE=IMAGE:324 218952_at 2661 7 7 gb:NM_013271.1 /DEF=Homo sapiens granin-like neuroendocrine peptide precursor (SAAS), mRNA. /FEA=mRNA /G 204033_at 2154 7 7 gb:NM_004237.1 /DEF=Homo sapiens thyroid hormone receptor interactor 13 (TRIP13), mRNA.
Load more

Recommended publications
  • Methods for Identifying Circadian Rhythm
    (19) *EP003302716B1* (11) EP 3 302 716 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61Q 17/04 (2006.01) G01N 33/50 (2006.01) (2006.01) (2006.01) 14.10.2020 Bulletin 2020/42 A61Q 19/08 A61Q 19/00 C12Q 1/68 (2018.01) (21) Application number: 16729482.6 (86) International application number: (22) Date of filing: 08.06.2016 PCT/US2016/036401 (87) International publication number: WO 2016/200905 (15.12.2016 Gazette 2016/50) (54) METHODS FOR IDENTIFYING CIRCADIAN RHYTHM-DEPENDENT COSMETIC AGENTS FOR SKIN CARE COMPOSITIONS VERFAHREN ZUR IDENTIFIZIERUNG VON BIORHYTHMUSABHÄNGIGEN KOSMETISCHEN MITTELN FÜR HAUTPFLEGEZUSAMMENSETZUNGEN PROCÉDÉS D’IDENTIFICATION D’AGENTS COSMÉTIQUES DÉPENDANT DU RYTHME CIRCADIEN POUR DES COMPOSITIONS DE SOIN DE LA PEAU (84) Designated Contracting States: • OSBORNE, Rosemarie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Cincinnati, Ohio 45202 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: P&G Patent Belgium UK N.V. Procter & Gamble Services Company S.A. (30) Priority: 08.06.2015 US 201562172498 P Temselaan 100 1853 Strombeek-Bever (BE) (43) Date of publication of application: 11.04.2018 Bulletin 2018/15 (56) References cited: WO-A1-2010/079285 JP-A- 2010 098 965 (73) Proprietor: The Procter & Gamble Company US-A1- 2009 220 481 US-A1- 2010 028 317 Cincinnati, OH 45202 (US) US-A1- 2015 071 895 (72) Inventors: • GEYFMAN MIKHAIL ET AL: "Clock genes, hair • MULLINS, Lisa, Ann growth and aging", AGING, NEW YORK, NY, US, Cincinnati, Ohio 45202 (US) vol.
    [Show full text]
  • The Mineralocorticoid Receptor Leads to Increased Expression of EGFR
    www.nature.com/scientificreports OPEN The mineralocorticoid receptor leads to increased expression of EGFR and T‑type calcium channels that support HL‑1 cell hypertrophy Katharina Stroedecke1,2, Sandra Meinel1,2, Fritz Markwardt1, Udo Kloeckner1, Nicole Straetz1, Katja Quarch1, Barbara Schreier1, Michael Kopf1, Michael Gekle1 & Claudia Grossmann1* The EGF receptor (EGFR) has been extensively studied in tumor biology and recently a role in cardiovascular pathophysiology was suggested. The mineralocorticoid receptor (MR) is an important efector of the renin–angiotensin–aldosterone‑system and elicits pathophysiological efects in the cardiovascular system; however, the underlying molecular mechanisms are unclear. Our aim was to investigate the importance of EGFR for MR‑mediated cardiovascular pathophysiology because MR is known to induce EGFR expression. We identifed a SNP within the EGFR promoter that modulates MR‑induced EGFR expression. In RNA‑sequencing and qPCR experiments in heart tissue of EGFR KO and WT mice, changes in EGFR abundance led to diferential expression of cardiac ion channels, especially of the T‑type calcium channel CACNA1H. Accordingly, CACNA1H expression was increased in WT mice after in vivo MR activation by aldosterone but not in respective EGFR KO mice. Aldosterone‑ and EGF‑responsiveness of CACNA1H expression was confrmed in HL‑1 cells by Western blot and by measuring peak current density of T‑type calcium channels. Aldosterone‑induced CACNA1H protein expression could be abrogated by the EGFR inhibitor AG1478. Furthermore, inhibition of T‑type calcium channels with mibefradil or ML218 reduced diameter, volume and BNP levels in HL‑1 cells. In conclusion the MR regulates EGFR and CACNA1H expression, which has an efect on HL‑1 cell diameter, and the extent of this regulation seems to depend on the SNP‑216 (G/T) genotype.
    [Show full text]
  • KIAA0101/P15paf) Over Expression and Gene Copy Number Alterations in Hepatocellular Carcinoma Tissues
    PCNA-associated Factor (KIAA0101/p15PAF) over expression and Gene Copy Number Alterations in Hepatocellular Carcinoma Tissues Anchalee Tantiwetrueangdet Research Center, Faculty of Medicine, Ramathibodi Hospital Ravat Panvichian ( [email protected] ) Mahidol University Faculty of Medicine Ramathibodi Hospital https://orcid.org/0000-0001-5282-8166 Pattana Sornmayura Department of Pathology, Faculty of Medicine, Ramathibodi Hospital Surasak Leelaudomlipi Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Research article Keywords: PCNA-associated factor (KIAA0101/p15PAF), droplet digital PCR, real-time PCR, p53 tumor suppressor protein, Ki-67 proliferation marker protein, HCC DOI: https://doi.org/10.21203/rs.3.rs-39782/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/18 Abstract Background PCNA-associated factor (KIAA0101/p15PAF) is a cell-cycle regulated oncoprotein that regulates DNA synthesis, maintenance of DNA methylation, and DNA-damage bypass, through the interaction with the human sliding clamp PCNA. KIAA0101 is overexpressed in various cancers, including hepatocellular carcinoma (HCC). However, it remains unknown whether KIAA0101 gene ampliƒcation occurs and causally correlates with the KIAA0101 overexpression in HCC. This question is relevant to the development of the optimal test(s) for KIAA0101 and the strategies to target KIAA0101 in HCC. Methods In this study, we validated KIAA0101 mRNA expression levels by quantitative real-time PCR in 40 pairs of snap-frozen HCC and matched-non-cancerous tissues; we then evaluated KIAA0101 gene copy numbers by droplet digital PCR (ddPCR) in 36 pairs of the tissues. Besides, KIAA0101 protein expression was detected by immunohistochemistry (IHC) in 81 pairs of formalin-ƒxed para∆n-embedded (FFPE) tissues.
    [Show full text]
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short
    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Mucosal Effects of Tenofovir 1%
    RESEARCH ARTICLE elifesciences.org Mucosal effects of tenofovir 1% gel Florian Hladik1,2,3*, Adam Burgener4,5†, Lamar Ballweber3†, Raphael Gottardo3,6,7, Lucia Vojtech1, Slim Fourati8, James Y Dai6,7, Mark J Cameron8, Johanna Strobl3, Sean M Hughes1, Craig Hoesley9, Philip Andrew10, Sherri Johnson10, Jeanna Piper11, David R Friend12, T Blake Ball4,5, Ross D Cranston13,14, Kenneth H Mayer15, M Juliana McElrath2,3,16, Ian McGowan13,14* 1Department of Obstetrics and Gynecology, University of Washington, Seattle, United States; 2Department of Medicine, University of Washington, Seattle, United States; 3Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, United States; 4Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada; 5National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Winnipeg, Canada; 6Department of Biostatistics, University of Washington, Seattle, United States; 7Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States; 8Vaccine and Gene Therapy Institute of Florida, Port Saint Lucie, United States; 9Department of Medicine, University of Alabama, Birmingham, United States; 10FHI 360, Durham, United States; 11Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States; 12CONRAD, Eastern Virginia Medical School, Arlington, United States; 13University of Pittsburgh School of Medicine, Pittsburgh, United States; 14Microbicide Trials Network, Magee-Women’s Research Institute, Pittsburgh, United States; 15Fenway Health, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, United States; 16Department of Global Health, University of Washington, Seattle, United States *For correspondence: fhladik@ fhcrc.org (FH); mcgowanim@ mwri.magee.edu (IMG) †These authors contributed Abstract Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against equally to this work HIV transmission.
    [Show full text]
  • Macropinocytosis Requires Gal-3 in a Subset of Patient-Derived Glioblastoma Stem Cells
    ARTICLE https://doi.org/10.1038/s42003-021-02258-z OPEN Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells Laetitia Seguin1,8, Soline Odouard2,8, Francesca Corlazzoli 2,8, Sarah Al Haddad2, Laurine Moindrot2, Marta Calvo Tardón3, Mayra Yebra4, Alexey Koval5, Eliana Marinari2, Viviane Bes3, Alexandre Guérin 6, Mathilde Allard2, Sten Ilmjärv6, Vladimir L. Katanaev 5, Paul R. Walker3, Karl-Heinz Krause6, Valérie Dutoit2, ✉ Jann N. Sarkaria 7, Pierre-Yves Dietrich2 & Érika Cosset 2 Recently, we involved the carbohydrate-binding protein Galectin-3 (Gal-3) as a druggable target for KRAS-mutant-addicted lung and pancreatic cancers. Here, using glioblastoma patient-derived stem cells (GSCs), we identify and characterize a subset of Gal-3high glio- 1234567890():,; blastoma (GBM) tumors mainly within the mesenchymal subtype that are addicted to Gal-3- mediated macropinocytosis. Using both genetic and pharmacologic inhibition of Gal-3, we showed a significant decrease of GSC macropinocytosis activity, cell survival and invasion, in vitro and in vivo. Mechanistically, we demonstrate that Gal-3 binds to RAB10, a member of the RAS superfamily of small GTPases, and β1 integrin, which are both required for macro- pinocytosis activity and cell survival. Finally, by defining a Gal-3/macropinocytosis molecular signature, we could predict sensitivity to this dependency pathway and provide proof-of- principle for innovative therapeutic strategies to exploit this Achilles’ heel for a significant and unique subset of GBM patients. 1 University Côte d’Azur, CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging (IRCAN), Nice, France. 2 Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
    [Show full text]
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Supplementary Material
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Page 1 / 45 SUPPLEMENTARY MATERIAL Appendix A1: Neuropsychological protocol. Appendix A2: Description of the four cases at the transitional stage. Table A1: Clinical status and center proportion in each batch. Table A2: Complete output from EdgeR. Table A3: List of the putative target genes. Table A4: Complete output from DIANA-miRPath v.3. Table A5: Comparison of studies investigating miRNAs from brain samples. Figure A1: Stratified nested cross-validation. Figure A2: Expression heatmap of miRNA signature. Figure A3: Bootstrapped ROC AUC scores. Figure A4: ROC AUC scores with 100 different fold splits. Figure A5: Presymptomatic subjects probability scores. Figure A6: Heatmap of the level of enrichment in KEGG pathways. Kmetzsch V, et al. J Neurol Neurosurg Psychiatry 2021; 92:485–493. doi: 10.1136/jnnp-2020-324647 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Appendix A1. Neuropsychological protocol The PREV-DEMALS cognitive evaluation included standardized neuropsychological tests to investigate all cognitive domains, and in particular frontal lobe functions. The scores were provided previously (Bertrand et al., 2018). Briefly, global cognitive efficiency was evaluated by means of Mini-Mental State Examination (MMSE) and Mattis Dementia Rating Scale (MDRS). Frontal executive functions were assessed with Frontal Assessment Battery (FAB), forward and backward digit spans, Trail Making Test part A and B (TMT-A and TMT-B), Wisconsin Card Sorting Test (WCST), and Symbol-Digit Modalities test.
    [Show full text]
  • Isoform-Specific Regulation of HCN4 Channels by a Family of Endoplasmic Reticulum Proteins
    Isoform-specific regulation of HCN4 channels by a family of endoplasmic reticulum proteins Colin H. Petersa, Mallory E. Myersa, Julie Juchnoa, Charlie Haimbaugha, Hicham Bichraouia, Yanmei Dub, John R. Bankstona, Lori A. Walkerb, and Catherine Proenzaa,b,1 aDepartment of Physiology and Biophysics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045; and bDepartment of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045 Edited by Bruce P. Bean, Harvard Medical School, Boston, MA, and approved June 5, 2020 (received for review April 13, 2020) Ion channels in excitable cells function in macromolecular com- (14). When HCN4 is expressed in HEK293 cells, it exhibits the plexes in which auxiliary proteins modulate the biophysical properties canonical depolarizing shift in voltage dependence in response to of the pore-forming subunits. Hyperpolarization-activated, cyclic cAMP. However, we found that when HCN4 is expressed in nucleotide-sensitive HCN4 channels are critical determinants of mem- Chinese hamster ovary (CHO) cells, channel activation is con- brane excitability in cells throughout the body, including thalamocort- stitutively shifted to more depolarized membrane potentials and ical neurons and cardiac pacemaker cells. We previously showed that is no longer affected by cAMP. Moreover, the constitutive acti- the properties of HCN4 channels differ dramatically in different cell vation of HCN4 in CHO cells is specific to the HCN4 isoform; types, possibly due to the endogenous expression of auxiliary pro- HCN2 retains a large cAMP-dependent shift in voltage de- teins. Here, we report the discovery of a family of endoplasmic re- pendence (14). We hypothesized that this “CHO effect” is due to ticulum (ER) transmembrane proteins that associate with and expression of an endogenous, isoform-specific modulator of modulate HCN4.
    [Show full text]
  • Ion Channels 3 1
    r r r Cell Signalling Biology Michael J. Berridge Module 3 Ion Channels 3 1 Module 3 Ion Channels Synopsis Ion channels have two main signalling functions: either they can generate second messengers or they can function as effectors by responding to such messengers. Their role in signal generation is mainly centred on the Ca2 + signalling pathway, which has a large number of Ca2+ entry channels and internal Ca2+ release channels, both of which contribute to the generation of Ca2 + signals. Ion channels are also important effectors in that they mediate the action of different intracellular signalling pathways. There are a large number of K+ channels and many of these function in different + aspects of cell signalling. The voltage-dependent K (KV) channels regulate membrane potential and + excitability. The inward rectifier K (Kir) channel family has a number of important groups of channels + + such as the G protein-gated inward rectifier K (GIRK) channels and the ATP-sensitive K (KATP) + + channels. The two-pore domain K (K2P) channels are responsible for the large background K current. Some of the actions of Ca2 + are carried out by Ca2+-sensitive K+ channels and Ca2+-sensitive Cl − channels. The latter are members of a large group of chloride channels and transporters with multiple functions. There is a large family of ATP-binding cassette (ABC) transporters some of which have a signalling role in that they extrude signalling components from the cell. One of the ABC transporters is the cystic − − fibrosis transmembrane conductance regulator (CFTR) that conducts anions (Cl and HCO3 )and contributes to the osmotic gradient for the parallel flow of water in various transporting epithelia.
    [Show full text]
  • Spatial Distribution of Leading Pacemaker Sites in the Normal, Intact Rat Sinoa
    Supplementary Material Supplementary Figure 1: Spatial distribution of leading pacemaker sites in the normal, intact rat sinoatrial 5 nodes (SAN) plotted along a normalized y-axis between the superior vena cava (SVC) and inferior vena 6 cava (IVC) and a scaled x-axis in millimeters (n = 8). Colors correspond to treatment condition (black: 7 baseline, blue: 100 µM Acetylcholine (ACh), red: 500 nM Isoproterenol (ISO)). 1 Supplementary Figure 2: Spatial distribution of leading pacemaker sites before and after surgical 3 separation of the rat SAN (n = 5). Top: Intact SAN preparations with leading pacemaker sites plotted during 4 baseline conditions. Bottom: Surgically cut SAN preparations with leading pacemaker sites plotted during 5 baseline conditions (black) and exposure to pharmacological stimulation (blue: 100 µM ACh, red: 500 nM 6 ISO). 2 a &DUGLDFIoQChDQQHOV .FQM FOXVWHU &DFQDG &DFQDK *MD &DFQJ .FQLS .FQG .FQK .FQM &DFQDF &DFQE .FQM í $WSD .FQD .FQM í .FQN &DVT 5\U .FQM &DFQJ &DFQDG ,WSU 6FQD &DFQDG .FQQ &DFQDJ &DFQDG .FQD .FQT 6FQD 3OQ 6FQD +FQ *MD ,WSU 6FQE +FQ *MG .FQN .FQQ .FQN .FQD .FQE .FQQ +FQ &DFQDD &DFQE &DOP .FQM .FQD .FQN .FQG .FQN &DOP 6FQD .FQD 6FQE 6FQD 6FQD ,WSU +FQ 6FQD 5\U 6FQD 6FQE 6FQD .FQQ .FQH 6FQD &DFQE 6FQE .FQM FOXVWHU V6$1 L6$1 5$ /$ 3 b &DUGLDFReFHSWRUV $GUDF FOXVWHU $GUDD &DY &KUQE &KUP &KJD 0\O 3GHG &KUQD $GUE $GUDG &KUQE 5JV í 9LS $GUDE 7SP í 5JV 7QQF 3GHE 0\K $GUE *QDL $QN $GUDD $QN $QN &KUP $GUDE $NDS $WSE 5DPS &KUP 0\O &KUQD 6UF &KUQH $GUE &KUQD FOXVWHU V6$1 L6$1 5$ /$ 4 c 1HXURQDOPURWHLQV
    [Show full text]